BioTech IP Review

Publication Number: WO 2025193609 A1
Filing Date: March 11, 2024
Publication Date: September 18, 2025
Applicant / Assignee: Caribou Biosciences, Inc.
Priority Claim: Based on a U.S. provisional application filed March 11, 2024

---

What This Patent Covers

This international patent application describes improved analytical methods and molecular compositions for accurately measuring nucleic acid transcripts and transcript isoforms within individual cells or cell populations. Such assessments are especially important for quality control of engineered cell therapies such as CAR‑T and CAR‑NK cells.

Key elements of the invention include:

• Sensitive transcript detection: Methods to detect and quantify specific RNA transcripts and their isoforms in cells using streamlined and cost‑effective workflows. These approaches can be essential for confirming gene expression patterns in CRISPR‑edited immune cells prior to clinical use.
• Compositions & reagents: Novel reagents or probe sets that facilitate transcript analysis with improved specificity and throughput, enabling manufacturers to profile engineered cells quickly and reliably.
• Applications in cell therapy QC: The methods are particularly useful as quality‑control tools in the production of engineered T‑cells and NK cells (e.g., CAR‑T products), where confirming expected gene expression and the absence of unwanted transcripts is critical for safety and efficacy.

---

Why This Patent Is Important

1) Supports CAR‑T Cell Manufacturing Quality
Caribou’s core clinical programs (e.g., CB‑010 and CB‑011 allogeneic CAR‑T therapies) require rigorous QC of transcriptomes to ensure that engineered cells have appropriate expression profiles. This patent provides technology for improved verification of transcript identity and abundance, directly supporting manufacturing and regulatory submissions.

2) Broad Utility Across Cell Therapy Platforms
Although focused on transcript analysis, the technology can be applied across a wide range of engineered cell types, increasing its commercial reach beyond a single product. It could be licensed to other cell therapy developers or incorporated into internal workflows.

3) Enabling Infrastructure for Clinical & Regulatory Success
Accurate characterization of engineered cells is a key requirement for regulatory approval of advanced therapies. Proprietary methods that streamline this process can reduce cost, improve reproducibility, and provide defensible data packages — strengthening Caribou’s competitive position.

4) Adds Depth to Caribou’s IP Portfolio
While Caribou’s patents often focus on CRISPR editing and CAR constructs, this application extends IP into analytics and QC technology, an increasingly critical part of commercial cell therapy manufacturing.